Related references
Note: Only part of the references are listed.Clinical Pharmacokinetics of Gabapentin After Administration of Gabapentin Enacarbil Extended-Release Tablets in Patients With Varying Degrees of Renal Function Using Data From an Open-Label, Single-Dose Pharmacokinetic Study
Ritu Lal et al.
CLINICAL THERAPEUTICS (2012)
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Christina A. Rabinak et al.
ARCHIVES OF NEUROLOGY (2010)
Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine
Ritu Lal et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Long-term Maintenance Treatment of Restless Legs Syndrome With Gabapentin Enacarbil: A Randomized Controlled Study
Richard K. Bogan et al.
MAYO CLINIC PROCEEDINGS (2010)
Restless legs syndrome: Understanding its consequences and the need for better treatment
Christopher J. Earley et al.
SLEEP MEDICINE (2010)
Gabapentin Enacarbil in Restless Legs Syndrome: A Phase 2b, 2-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Arthur S. Walters et al.
CLINICAL NEUROPHARMACOLOGY (2009)
Pharmacokinetics and Tolerability of Single Escalating Doses of Gabapentin Enacarbil: A Randomized-Sequence, Double-Blind, Placebo-Controlled Crossover Study in Healthy Volunteers
Ritu Lal et al.
CLINICAL THERAPEUTICS (2009)
Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS
C. A. Kushida et al.
NEUROLOGY (2009)
A Population Pharmacokinetic Model of Gabapentin Developed in Nonparametric Adaptive Grid and Nonlinear Mixed Effects Modeling
Kristin C. Carlsson et al.
THERAPEUTIC DRUG MONITORING (2009)
Clinical Pharmacokinetics of XP13512, a Novel Transported Prodrug of Gabapentin
Kenneth C. Cundy et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Flat dosing of carboplatin is justified in adult patients with normal renal function
Corine Ekhart et al.
CLINICAL CANCER RESEARCH (2006)
Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study
W Hening et al.
SLEEP MEDICINE (2004)
XP13512 [(±)-1-([(α-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug:: I.: Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters
KC Cundy et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
XP13512 [(±)-1-([(α-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug:: II.: Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys
KC Cundy et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Long-term treatment of restless legs syndrome with dopamine agonists
W Ondo et al.
ARCHIVES OF NEUROLOGY (2004)
Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS)
JW Winkelman et al.
SLEEP MEDICINE (2004)
Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome
AS Walters et al.
SLEEP MEDICINE (2003)
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology - A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health
RP Allen et al.
SLEEP MEDICINE (2003)
Population pharmacokinetics of gabapentin in infants and children
D Ouellet et al.
EPILEPSY RESEARCH (2001)
Share Paper
